Company / PP&E (Net)
Bicara Therapeutics Inc. PP&E (Net) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$155.0K
FY2024
5-year range
$155.0K / $202.0K
FY2023-FY2024
Trend
-23.3%
vs FY2023
Sector context
#184 of 193
Health Care
What the data says
Among 193 Health Care companies, Bicara Therapeutics Inc. is in the bottom 5% for pp&e (net).
Based on SEC 10-K filings.
$155,000 in FY2024.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 193This company $155.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2024, pp&e (net) decreased 23.3% year-over-year.
- Ranks #184 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $155.0K | -23.3% |
| FY2023 | $202.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026